BNTX:NASDAQ
BioNTech SE - ADR
$98.13
arrow_downward
-0.54%(-0.53) 1D
$99.00
arrow_upward
+0.89% (+0.87)bedtimeAfter hours
Closed: Sep 9, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BNTX...
Open
$98.50
High
$98.64
Low
$96.87
Mkt. cap
24.65B
Avg. vol.
1.54M
Volume
0.00
52-wk high
$123.98
52-wk low
$79.52
EPS
-$7.80
Beta
1.27
Shares outstanding
251.20M
No. of employees
8K
Open
$98.50
High
$98.64
Low
$96.87
Mkt. cap
24.65B
Avg. vol.
1.54M
Volume
0.00
52-wk high
$123.98
52-wk low
$79.52
EPS
-$7.80
Beta
1.27
Shares outstanding
251.20M
No. of employees
8K
News stories
From web sources and news partners
ad-hoc-news.de
·
4 hours ago
BioNTech's Insider Trades and Pipeline Bet: Two Signals, One Stock
Stock Titan
·
7 hours ago
BioNTech (BNTX) CEO sells part of his stake under preset trading plan
ad-hoc-news.de
·
12 hours ago
BioNTech's Seoul Moment: Can Two Antibodies Carry a Story That COVID Revenue No Longer Supports?
Zacks
·
17 hours ago
Pfizer Stock Rises Almost 9% in 3 Months: Time to Buy, Hold or Exit?
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR